Director granted 2,306 stock options at $2.71 in Cardio Diagnostics (CDIO)

Rhea-AI Filing Summary

Cardio Diagnostics Holdings, Inc. director Wendy J. Betts reported a stock option grant. On December 31, 2025, she was awarded 2,306 stock options with a right to buy common stock at an exercise price of $2.71 per share. After this grant, she beneficially owns 6,308 derivative securities in the form of stock options, held with direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Betts Wendy J

(Last) (First) (Middle)

C/O CARDIO DIAGNOSTICS HOLDINGS INC.

311 W. SUPERIOR ST. SUITE 444

(Street)

CHICAGO IL 60654

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cardio Diagnostics Holdings, Inc. [ CDIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$2.71	12/31/2025		A		2,306		12/31/2025	12/31/2035	Common Stock	2,306	$2.71	6,308	D

Explanation of Responses:

	/s/ Elisa Luqman as attorney-in-fact for Wendy Betts	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cardio Diagnostics (CDIO) report in this Form 4?

The filing reports that director Wendy J. Betts received a grant of 2,306 stock options (right to buy) in Cardio Diagnostics Holdings, Inc.

When did Wendy Betts receive the stock options reported for CDIO?

The stock options were granted on December 31, 2025, as shown in the transaction date field of the Form 4.

What is the exercise price of the Wendy Betts stock options for Cardio Diagnostics (CDIO)?

The options have a conversion or exercise price of $2.71 per share of Cardio Diagnostics common stock.

How many Cardio Diagnostics (CDIO) options does Wendy Betts hold after this transaction?

Following the reported grant, Wendy Betts beneficially owns 6,308 derivative securities, all in the form of stock options.

Are Wendy Betts’s CDIO stock options held directly or indirectly?

The Form 4 indicates direct ownership of the 6,308 stock options, with no nature of indirect beneficial ownership listed.

What does transaction code "A" mean in the Wendy Betts Form 4 for CDIO?

Transaction code "A" in the Form 4 indicates an acquisition of derivative securities, in this case a grant of stock options.

What are the key terms of the stock options granted to Wendy Betts for Cardio Diagnostics (CDIO)?

The derivative security is Stock Options (Right to Buy) for 2,306 underlying shares of common stock at an exercise price of $2.71 per share, with the Form 4 showing the same date of December 31, 2025 for grant and exercisability.